OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms OPTIMIS
- Sponsors Bayer
- 15 Aug 2017 Planned End Date changed from 22 Jul 2017 to 22 Oct 2017.
- 12 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
- 12 Aug 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.